Semaglutide

At a Glance

Molecular Properties

Overview

Compound Description

Semaglutide is a synthetic 31-amino-acid peptide analog of human glucagon-like peptide-1 (GLP-1) that has been one of the most extensively studied incretin-based research compounds. The molecule features a substitution of alanine to alpha-aminoisobutyric acid (Aib) at position 8 for dipeptidyl peptidase-4 (DPP-4) resistance, and acylation of lysine at position 26 with a C18 fatty diacid chain that enables non-covalent albumin binding. These modifications extend the half-life to approximately 7 days. The compound has been investigated in the landmark STEP clinical trial program involving thousands of participants.

Mechanism of Action

Research-Identified Pathways

Key Research Findings

Published Study Highlights

• STEP 1 trial demonstrated mean weight reduction of 14.9% from baseline versus 2.4% with placebo over 68 weeks in participants with overweight or obesity
• STEP 3 trial investigated the compound as adjunct to intensive behavioral therapy, showing enhanced outcomes with combined intervention
• Research demonstrated improvements in cardiometabolic risk factors including blood pressure, lipid profiles, and inflammatory biomarkers
• Studies in prediabetic populations showed significant improvements in glucose metabolism and glycemic status metrics
• The STEP 5 trial extension provided two-year efficacy data demonstrating sustained weight management effects

Areas of Research Interest

Why Researchers Are Investigating This Compound

This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.

• Weight management research: the most widely discussed GLP-1 agonist, with the STEP trial program generating enormous interest in metabolic regulation pathways
• Appetite and food behavior science: researchers are investigating its central nervous system effects on appetite signaling and food preference patterns
• Cardiovascular risk factor research: its observed effects on multiple cardiometabolic parameters have attracted interest from cardiology researchers
• Metabolic syndrome investigation: its effects across multiple metabolic parameters have made it a focus of comprehensive metabolic health research

Published Research

Peer-Reviewed References

1. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine (2021). doi:10.1056/NEJMoa2032183
2. Wadden TA, Bailey TS, Billings LK, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial." JAMA (2021). doi:10.1001/jama.2021.1831
3. Garvey WT, Batterham RL, Bhatta M, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nature Medicine (2022). doi:10.1038/s41591-022-02026-4
4. Rubino DM, Greenway FL, Khalid U, et al. "Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program." Diabetes Care (2022). doi:10.2337/dc21-1785